A.B.Series Apple Stem Cell Serum
A.B.Series Apple Stem Cell Serum A natural way to rejuvenate and revitalize your skin for a younger you. Apple Stem Cell Serum is formulated from Switzerland based on the Uttwiler Spatlauber...
By: AVAIL Beauty
The rest is here:
A.B.Series Apple Stem Cell Serum - Video
Boston, MA (PRWEB) July 31, 2014
Bostons Adult Stem Cell Technology Center, LLC (ASCTC) finds itself flush with innovative adult stem cell biotechnologies. Currently the company holds seven recently issued patents and has three additional patent applications currently under examination by the U.S. Patent and Trademarks Office.
The patented inventions address two of the most vexing problems in adult stem cell biology research and regenerative medicine. Adult stem cells are difficult to identify; and they have been difficult to multiply to sufficient numbers to support regenerative medicine applications.
ASCTC has addressed the identity problem by developing patented biomarkers that are found exclusively on adult stem cells. The biomarkers are based on ASCTCs expertise in defining properties of adult stem cells that are not shared by any other normal cell types in the body. The patented biomarkers also identify some types of cancer stem cells. Therefore, they have applications in both stem cell medicine and cancer medicine.
ASCTCa success in developing procedures for producing adult stem cells in large numbers is due to the companys expertise in adult stem cell growth control. ASCTCs technology uses natural compounds found in the body to instruct adult stem cells to multiply in a controlled manner as during normal body growth.
The companys patented method for controlling adult stem cells to multiply without losing their stem cell properties has applications for many different types of adult stem cells. ASCTCs approved patents demonstrate the application of the method for production of human liver stem cells, hair follicle stem cells, and human pancreatic stem cells; but the technology has general application to adult stem cells found in many other types of organs and tissues.
In addition to the main focus on adult stem cell technologies, ASCTCs most recently issued patent applies its cell multiplication methods to produce induced pluripotent stem cells (iPSCs) without transferring exogenous genes. This gene-free single agent method should offer significant value to the many mushrooming companies that supply iPSCs and iPSC production reagents.
As a small start-up, ASCTC is employing a social media marketing strategy. In the past week, the company has launched patent licensing ads on LinkedIn, Vocus, and Facebook, as well increased its advertising references within its recently established Twitter presence.
It would be a shame for these technologies to lie dormant, just because our hands are full with other projects at the moment. James Sherley, director of ASCTC, relates that the companys two main business efforts require only a fraction of its available intellectual property. ASCTC is currently focused on bringing laboratory-scale production of human liver stem cells to manufacturing scales and developing a computer simulation assay for preclinical detection of drug candidates with intolerable toxicity due to adverse effects on adult stem cells.
Sherley adds, We already have a few companies that have expressed interest in licensing. But we could do a lot better at reaching others whose development efforts would benefit from ASCTCs unique technologies. Love to hear from ViaCyte!
Original post:
The Adult Stem Cell Technology Center, LLC Launches A Marketing Campaign To License Adult Stem Cell Biotechnologies
By Amy Norton HealthDay Reporter
WEDNESDAY, July 30, 2014 (HealthDay News) -- Babies born with so-called "bubble boy" disease can often be cured with a stem cell transplant, regardless of the donor -- but early treatment is critical, a new study finds.
Severe combined immunodeficiency (SCID), as the condition is medically known, actually refers to a group of rare genetic disorders that all but eliminate the immune system. That leaves children at high risk of severe infections.
The term "bubble boy" became popular after a Texas boy with SCID lived in a plastic bubble to ward off infections. The boy, David Vetter, died in 1984 at the age of 12, after an unsuccessful bone marrow transplant -- an attempt to give him a functioning immune system.
Today, children with SCID have a high chance of survival if they receive an early stem cell transplant, researchers report in the July 31 issue of the New England Journal of Medicine.
In the best-case scenario, a child would get stem cells -- the blood-forming cells within bone marrow -- from a sibling who is a perfect match for certain immune-system genes.
But that's not always an option, partly because kids with SCID are often their parents' first child, said Dr. John Cunningham, director of hematopoietic stem cell transplantation at the University of Chicago Comer Children's Hospital. He was not involved in the study.
In those cases, doctors typically turn to a parent -- who is usually a "half" match, but whose stem cells can be purified to improve the odds of success. Sometimes, stem cells from an unrelated, genetically matched donor can be used.
The good news: Regardless of the donor, children with SCID can frequently be cured, according to the new findings. But early detection and treatment is vital.
"These findings show that if you do these transplants early -- before [the age of] 3.5 months, in a child without infection -- the results are really quite comparable to what you have with a matched sibling," said lead researcher Dr. Richard O'Reilly, chief of the pediatric bone marrow transplant service at Memorial Sloan-Kettering Cancer Center in New York City.
View original post here:
Early Stem Cell Transplant Vital in 'Bubble Boy' Disease
"Bubble boy" David Vetter lived in a protective environment designed by NASA engineers. He died of complications after receiving a bone marrow transplant in 1984, at the age of 12. Baylor College of Medicine Photo Archives
Babies born with so-called "bubble boy" disease can often be cured with a stem cell transplant, regardless of the donor -- but early treatment is critical, a new study finds.
Severe combined immunodeficiency (SCID), as the condition is medically known, actually refers to a group of rare genetic disorders that all but eliminate the immune system. That leaves children at high risk of severe infections.
The term "bubble boy" became popular after a Texas boy with SCID lived in a plastic bubble to ward off infections. The boy, David Vetter, died in 1984 at the age of 12, after an unsuccessful bone marrow transplant -- an attempt to give him a functioning immune system.
15 Photos
Immune disorder forced David Vetter to live in bubble - but breakthroughs from his story now enable similar kids to live free
In the best-case scenario, a child would get stem cells -- the blood-forming cells within bone marrow -- from a sibling who is a perfect match for certain immune-system genes.
But that's not always an option, partly because kids with SCID are often their parents' first child, said Dr. John Cunningham, director of hematopoietic stem cell transplantation at the University of Chicago Comer Children's Hospital. He was not involved in the study.
In those cases, doctors typically turn to a parent -- who is usually a "half" match, but whose stem cells can be purified to improve the odds of success. Sometimes, stem cells from an unrelated, genetically matched donor can be used.
The good news: Regardless of the donor, children with SCID can frequently be cured, according to the new findings. But early detection and treatment is vital.
Excerpt from:
Early stem cell transplant may cure "bubble boy" disease
What clinical trials for gene and stem cell therapy are under way in your London laboratory?
Robin Ali, BSc, PhD, FMedSci, internationally known for his research in gene and cell-based therapy for the treatment of retinal degeneration, has joined the U-M Department of Ophthalmology...
By: Kellogg Eye Center - Ann Arbor
Continued here:
What clinical trials for gene and stem cell therapy are under way in your London laboratory? - Video
Stem Cells and Stem Cell Research - Ask Dr Moore - Houston Foot and Ankle Surgeon
Simply put, stem cells are basic #39;progenitor cells #39; that have all the DNA and information to differentiate into any structure and system in the body. The form naturally after fertilization...
By: Moore Foot and Ankle Specialists - Dr. Robert J Moore III
View original post here:
Stem Cells and Stem Cell Research - Ask Dr Moore - Houston Foot and Ankle Surgeon - Video
And the Beat Goes On - Advances in Cardiac Care, Part 1
From interventional cardiology and the use of intravascular ultrasound to using stem cells to regenerate heart muscle, this program brings together an array of experts from several fields who...
By: UWTV
See the original post:
And the Beat Goes On - Advances in Cardiac Care, Part 1 - Video
And the Beat Goes On - Advances in Cardiac Care, Part 2
From interventional cardiology and the use of intravascular ultrasound to using stem cells to regenerate heart muscle, this program brings together an array of experts from several fields who...
By: UWTV
See the rest here:
And the Beat Goes On - Advances in Cardiac Care, Part 2 - Video
Knee arthritis 28 months after stem cell therapy by Harry Adelson, N.D.
Cory describes his outcome from a single bone marrow/adipose stem cell treatment for his arthritic knees by Harry Adelson, N.D. http://www.docereclinics.com.
By: Harry Adelson, N.D.
Read more:
Knee arthritis 28 months after stem cell therapy by Harry Adelson, N.D. - Video
Heal Interstitial Cystitis with Stem Cell Therapy
via YouTube Capture.
By: Minecraft madness and mayhem
See original here:
Heal Interstitial Cystitis with Stem Cell Therapy - Video
A new stem-cell discovery might one day lead to a more streamlined process for obtaining stem cells, which in turn could be used in the development of replacement tissue for failing body parts, according to UC San Francisco scientists who reported the findings in the current edition of Cell.
The work builds on a strategy that involves reprogramming adult cells back to an embryonic state in which they again have the potential to become any type of cell.
The efficiency of this process may soon increase thanks to the scientists identification of biochemical pathways that can inhibit the necessary reprogramming of gene activity in adult human cells. Removing these barriers increased the efficiency of stem-cell production, the researchers found.
Our new work has important implications for both regenerative medicine and cancer research, said Miguel Ramalho-Santos, Ph.D., associate professor of obstetrics, gynecology and reproductive sciences and a member of the Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research at UCSF, who led the research, funded in part by a prestigious NIH Directors New Innovator Award.
The earlier discovery that it was possible to take specialized adult cells and reverse the developmental clock to strip the mature cells of their distinctive identities and characteristics and to make them immortal, reprogrammable cells that theoretically can be used to replace any tissue type led to a share of the Nobel Prize in Physiology or Medicine being awarded to UCSF, Gladstone Institutes and Kyoto University researcher Shinya Yamanaka, M.D., in 2012.
These induced pluripotent stem (iPS) cells are regarded as an alternative experimental approach to ongoing efforts to develop tissue from stem cells obtained from early-stage human embryos. However, despite the promise of iPS cells and the excitement surrounding iPS research, the percentage of adult cells successfully converted to iPS cells is typically low, and the resultant cells often retain traces of their earlier lives as specialized cells.
Researchers generate stem cells by forcing the activation within adult cells of pluripotency-inducing genes starting with the so-called Yamanaka factors a process that turns back the clock on cellular maturation.
Yet, as Ramalho-Santos notes, From the time of the discovery of iPS cells, it was appreciated that the specialized cells from which they are derived are not a blank slate. They express their own genes that may resist or counter reprogramming.
But the nature of what exactly was getting in the way of reprogramming remained poorly understood. Now, by genetically removing multiple barriers to reprogramming, we have found that the efficiency of generation of iPS cells can be greatly increased, he said. The discovery will contribute to accelerating the safe and efficient use of iPS cells and other reprogrammed cells, according to Ramalho-Santos.
Miguel Ramalho-Santos
View post:
Stem cell discovery may make tissue regeneration more efficient
24 Hours of Stem Cells - 2013 Welcome
24 Hour Stem Cells is a virtual event produced by Life Technologies for Stem Cell Researchers all over the world. This video walks through the event and how to navigate through the virtual...
By: Life Technologies
Stem Cells to Renew the Health and Lives of People - Aishwarya Rai Bachchan in Chennai
Stem Cells to Renew the Health and Lives of People - Aishwarya Rai Bachchan in Chennai - RedPix 24x7 #AishwaryaRai #AishwaryaRaiBachchan #StemCells #LifeCell LifeCell is India #39;s first and...
By: Red Pix 24x7
Read the original:
Stem Cells to Renew the Health and Lives of People - Aishwarya Rai Bachchan in Chennai - Video
Contact Information
Available for logged-in reporters only
Newswise A new stem-cell discovery might one day lead to a more streamlined process for obtaining stem cells, which in turn could be used in the development of replacement tissue for failing body parts, according to UC San Francisco scientists who reported the findings in the current edition of Cell.
The work builds on a strategy that involves reprogramming adult cells back to an embryonic state in which they again have the potential to become any type of cell.
The efficiency of this process may soon increase thanks to the scientists identification of biochemical pathways that can inhibit the necessary reprogramming of gene activity in adult human cells. Removing these barriers increased the efficiency of stem-cell production, the researchers found.
Our new work has important implications for both regenerative medicine and cancer research, said Miguel Ramalho-Santos, PhD, associate professor of obstetrics, gynecology and reproductive sciences and a member of the Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research at UCSF, who led the research, funded in part by a prestigious NIH Directors New Innovator Award.
The earlier discovery that it was possible to take specialized adult cells and reverse the developmental clock to strip the mature cells of their distinctive identities and characteristics and to make them immortal, reprogrammable cells that theoretically can be used to replace any tissue type led to a share of the Nobel Prize in Physiology or Medicine being awarded to UCSF, Gladstone Institutes and Kyoto University researcher Shinya Yamanaka, MD, in 2012.
These induced pluripotent stem (iPS) cells are regarded as an alternative experimental approach to ongoing efforts to develop tissue from stem cells obtained from early-stage human embryos. However despite the promise of iPS cells and the excitement surrounding iPS research, the percentage of adult cells successfully converted to iPS cells is typically low, and the resultant cells often retain traces of their earlier lives as specialized cells.
Researchers generate stem cells by forcing the activation within adult cells of pluripotency-inducing genes starting with the so-called Yamanaka factors a process that turns back the clock on cellular maturation.
Yet, as Ramalho-Santos notes, From the time of the discovery of iPS cells, it was appreciated that the specialized cells from which they are derived are not a blank slate. They express their own genes that may resist or counter reprogramming.
Go here to read the rest:
Stem Cell Advance May Increase Efficiency of Tissue Regeneration
What is Okyanos Cardiac Stem Cell Therapy?
Cardiac stem cell therapy is a promising new treatment option for advanced heart disease patients. This short video explores the procedure and benefits of adult stem cell therapy for severe...
By: Okyanos Heart Institute
Continue reading here:
What is Okyanos Cardiac Stem Cell Therapy? - Video
Tampa Bay, FL (PRWEB) July 28, 2014
Nearly 53 million Americans today are suffering with arthritis, with the majority of them diagnosed with osteoarthritis. (1) Osteoarthritis is a degeneration of joint cartilage and its underlying bone, causing significant pain and stiffness. While osteoarthritis has no cure, stem cell therapy has been demonstrated to induce profound healing in many forms of arthritis, according to the Stem Cell Institute. (2) Dr. Cynthia Elliott of Skinspirations, a center for cosmetic enhancement devoted to non-surgical aesthetics and now also specializing in administering regenerative medicine by stem cell, has made use of these services in a recent case study, which resulted in improved health in one of their clients.
Stem cells are unique from other cells for the following reasons:
(a)They can renew themselves through cell division; and (b)Under certain conditions, they can become tissue or organ-specific cells.
Stem cells are revered for their ability to make replacement tissues, as it relates to regenerative therapy. (3) Medical scientists and researchers are discovering the seemingly endless possibilities of what stem cells can treat, including brain damage, bone repair, kidney disease, etc. (4) This treatment is starting to boom in the medical world as a viable procedure, but Skinspirations has already had these practices in place, establishing them as progressive practitioners in the field.
Skinspirations is specifically studying the Stromal Vascular Fraction (SVF)another term for stem cell treatmentand how it affects knees with severe arthritis. According to Dr. Elliott, Stromal Vascular Fraction can help to repair, replace and restore any damaged cells within the bodyDr. Elliott performed the stem cell procedure on her uncle after first treating other patients during her training, and he experienced the following results:
Case in Point:
Joe Elliott, a 63-year-old male, had severe arthritis in one knee. Doctors advised him to get a knee replacement, but Joe was hoping to avoid surgery for as long as possible. After talking to Dr. Elliott about the treatment, he drove to Skinspirations from Missouri to go forward with the stem cell procedure.
Dr. Elliott performed the treatment with the following steps:
(1)Numbed his abdomen with anesthesia; (2)Removed about 100 cc of fat; (3)Processed the fat to isolate the SVF; (4)Numbed the arthritic knee; and (5)Injected the pellet of SVF into the joint of his arthritic knee.
Read more from the original source:
Skinspirations Study Supports Medical Findings: Stem Cell Treatment Triggers Tissue Regeneration
The California Institute for Regenerative Medicine has continued in damage-control mode since the state agencys former president, Alan Trounson, joined the board of directors at StemCells Inc. this month, just seven days after leaving the agency.
Newark-based StemCells has been awarded nearly $20 million in CIRM funding, as part of a long relationship that, in the wake of Trounson's departure, has raised concern about potential conflict of interest.
The agency's new president, C. Randal Mills, said he was taking a strong stand on personal ethics, signing an agreement not to accept a job with any company funded by CIRM for at least one year after leaving his position at the state agency.
"We take even the appearance of conflicts of interest very seriously," Mills said in a statement this month.
But a scientist whose grant proposal was turned down even though it received a higher rating than the StemCells proposal called the relationship between the state agency and the company interesting.
In my opinion, Mr. Trounson and the CIRM staff were clearly antagonistic to us and strongly supportive of StemCells, Lon S. Schneider, a scientist at USCs Keck School of Medicine, told the California Stem Cell Report ,a blog that follows news related to the stem cell agency.
And Times columnist Michael Hiltzik pointed out that the agency has hired its own law firm to conduct the investigation, rather than a completely independent party.
The unanswered question burning a hole through CIRM's credibility is whether StemCells Inc. got its money because its research was promising, or because it knew the right people, Hiltzik wrote.
The stem cell agency has also voted to cut $5 million from a $70-million effort to create a series of statewide stem cell clinics, according to the California Stem Cell Report. And even though the board has 29 members, only eight could vote because of conflicts of interest among the others, according to the report.
Following a thorough review it is my opinion that the $70-million price tag is not clearly justified in terms of the benefits it will deliver to the people of California, Mills wrote in a memo to the agency's board.
Read the original:
California stem cell agency head takes stand on 'personal ethics'
Scientists at The New York Stem Cell Foundation (NYSCF) Research Institute are one step closer to creating a viable cell replacement therapy for multiple sclerosis from a patient's own cells.
For the first time, NYSCF scientists generated induced pluripotent stem (iPS) cells lines from skin samples of patients with primary progressive multiple sclerosis and further, they developed an accelerated protocol to induce these stem cells into becoming oligodendrocytes, the myelin-forming cells of the central nervous system implicated in multiple sclerosis and many other diseases.
Existing protocols for producing oligodendrocytes had taken almost half a year to produce, limiting the ability of researchers to conduct their research. This study has cut that time approximately in half, making the ability to utilize these cells in research much more feasible.
Stem cell lines and oligodendrocytes allow researchers to "turn back the clock" and observe how multiple sclerosis develops and progresses, potentially revealing the onset of the disease at a cellular level long before any symptoms are displayed. The improved protocol for deriving oligodendrocyte cells will also provide a platform for disease modeling, drug screening, and for replacing the damaged cells in the brain with healthy cells generated using this method.
"We are so close to finding new treatments and even cures for MS. The enhanced ability to derive the cells implicated in the disease will undoubtedly accelerate research for MS and many other diseases," said Susan L. Solomon, NYSCF Chief Executive Officer.
"We believe that this protocol will help the MS field and the larger scientific community to better understand human oligodendrocyte biology and the process of myelination. This is the first step towards very exciting studies: the ability to generate human oligodendrocytes in large amounts will serve as an unprecedented tool for developing remyelinating strategies and the study of patient-specific cells may shed light on intrinsic pathogenic mechanisms that lead to progressive MS." said Dr. Valentina Fossati, NYSCF -- Helmsley Investigator and senior author on the paper.
In multiple sclerosis, the protective covering of axons, called myelin, becomes damaged and lost. In this study, the scientists not only improved the protocol for making the myelin-forming cells but they showed that the oligodendrocytes derived from the skin of primary progressive patients are functional, and therefore able to form their own myelin when put into a mouse model. This is an initial step towards developing future autologous cell transplantation therapies in multiple sclerosis patients
This important advance opens up critical new avenues of research to study multiple sclerosis and other diseases. Oligodendrocytes are implicated in many different disorders, therefore this research not only moves multiple sclerosis research forward, it allows NYSCF and other scientists the ability to study all demyelinating and central nervous system disorders.
"Oligodendrocytes are increasingly recognized as having an absolutely essential role in the function of the normal nervous system, as well as in the setting of neurodegenerative diseases,such as multiple sclerosis. The new work from the NYSCF Research Institute will help to improve our understanding of these important cells. In addition, being able to generate large numbers of patient-specific oligodendrocytes will support both cell transplantation therapeutics for demyelinating diseases and the identification of new classes of drugs to treat such disorders," said Dr. Lee Rubin, NYSCF Scientific Advisor and Director of Translational Medicine at the Harvard Stem Cell Institute.
Multiple sclerosis is a chronic, inflammatory, demyelinating disease of the central nervous system, distinguished by recurrent episodes of demyelination and the consequent neurological symptoms. Primary progressive multiple sclerosis is the most severe form of multiple sclerosis, characterized by a steady neurological decline from the onset of the disease. Currently, there are no effective treatments or cures for primary progressive multiple sclerosis and treatments relies merely on symptom management.
Continue reading here:
Cell therapy for multiple sclerosis patients: Closer than ever?
Stem cell agency President C. Randal Mills (left) and Chairman of the Board Jonathan Thomas.
Responding to his predecessor's ethically controversial departure, the president and chief executive of California's stem cell agency said Thursday he is taking legal steps to minimize conflicts of interests with those who have business before the agency.
C. Randal Mills said he will not take a job with any company funded by the California Institute for Regenerative Medicine for one year after he departs the agency. In addition, he also will not accept gifts or travel payments from any company, institution or person who gets agency funding.
Mills' action, announced at the agency's meeting in Millbrae, will be enforced with a legal agreement he will sign. His action comes less than a month after he replaced Alan Trounson as the agency chief. One week after his departure, CIRM-funded StemCells Inc. announced it had appointed Trounson to its board. StemCells Inc. had received an award of nearly $20 million from the agency to develop a therapy for Alzheimers disease.
While Trounson's appointment wasn't illegal, critics said it was unseemly for him to join a company that had received agency funding so soon after he left CIRM. An ethical controversy could harm the agency's chances of getting more funding from California voters, who gave the agency $3 billion with the passage of Proposition 71 in 2004.
Mills said the new rules apply only to himself, because of his central role at CIRM.
"This specifically addresses an issue where an individual in an organization has a disproportionate amount of power, and I want to make sure it's known that power will not be abused," Mills said.
Mills made the right decision, said Jeanne Loring, a CIRM-funded stem cell researcher at The Scripps Research Institute.
"There's a difference between what is legal and what is ethical," said Loring, who attended the meeting. "And he's going to be pushing the needle a lot more toward the ethical side without worrying whether he can get away with stuff."
John Simpson of Santa Monica-based Consumer Watchdog, who has often criticized CIRM for conflicts of interest, also praised the decision.
See the original post here:
Stem cell agency tightens ethics rules
Sen. Nancy Binay. INQUIRER.net PHOTO
MANILAHealth Secretary Enrique Ona has expressed disappointment with Sen. Nancy Binay, who questioned the allocation of P70 million under Disbursement Acceleration Program for a stem cell research project of the Lung Center of the Philippines.
Binay had said the money could have been better spent on more beds for government hospitals.
Im so disappointed with the Senator rather than support the opportunities for our doctors to do all types of research, not just on stem cell Filipinos can jumpstart medical research, comparing it with research capacity of other countriesthats what I would want to hear from her, Ona said Friday on the sidelines of the Department of Healths distribution of awards to the unsung heroes of Typhoon Yolanda.
And I also wish to tell her, I hope she increases the funds for various research being conducted by our doctors, he added. Because if not, these doctors may just opt to work in other countries.
Speaking at the Senate finance committee hearing on Thursday, Ona confirmed that P70 million from DAP was used to fund a Bio-Regenerative Technology Program or Stem Cell Research aimed at harnessing stem cell research and technology to reconstruct new health cells, replacing cancer or dead cells.
According to Ona, medical research is important and its significance should not be compared to the lack of hospital beds.
I hope they dont simplify medical research with [the number of] beds, he said, adding that those making such comments appeared to have limited knowledge in medicine.
Ona said the government bought 8,000 to 10,000 beds for hospitals, though he acknowledged that it needed to buy 5,000 to 10,000 more.
Explaining stem cell research, Ona said he was looking at preventive, promotive, curative and even rehabilitation needs of the entire health sector.
See original here:
Binay hit for questioning DAP allocation for stem cell research